James Ellsmere, MD MSc FRCSC - PowerPoint PPT Presentation

About This Presentation
Title:

James Ellsmere, MD MSc FRCSC

Description:

... Small cases series Morbid obesity is risk factor for ... Department of Surgery, ... comparable to Laparoscopic Roux-en-Y Gastric Bypass, ... – PowerPoint PPT presentation

Number of Views:92
Avg rating:3.0/5.0
Slides: 57
Provided by: altafa
Category:

less

Transcript and Presenter's Notes

Title: James Ellsmere, MD MSc FRCSC


1
Sleeve Gastrectomy as the Primary Procedure
  • James Ellsmere, MD MSc FRCSC
  • Surgical Director, Weight Loss Program
  • QE II Health Sciences Centre
  • Dalhousie University, Halifax NS

2
Disclosure
  • Ethicon Endosurg speaking

3
Sleeve Gastrectomy
  • First used in staged approach for the super obese
  • Increasingly being used as primary procedure with
    good weight loss and resolution of obesity
    related comorbidities
  • Involves resecting the greater curvature of the
    stomach
  • Reduces ghrelin levels for up to a year

Gagner et al. Surg Obes Relat Dis 2009
4
Advantages
  • Low mortality rate (0.39 percent)
  • Low complication rate (3 to 8 percent)
  • Low reintervention rate
  • Preservation of the pylorus
  • Maintenance of physiological food passage
  • Avoidance of foreign material

5
Disadvantages
  • Long term follow-up is limited
  • Can exacerbate GERD
  • Leaks though manageable can be challenging

6
International SG Expert PanelConsensus Statement
  • Expert panelists were invited to participate
    according to their publications, knowledge and
    experience, and identification as surgeons who
    had performed 500 cases (gt12000 cases)
  • Topics for consensus
  • patient selection
  • contraindications
  • surgical technique
  • prevention of complications
  • management of complications

Rosenthal et al. Surg Obes Relat Dis 2012
7
Objectives
  • Review the ASMBS position on SG
  • Discuss the common criticisms of SG
  • Nova Scotia experience

8
ASMBS 2011 Position Statement
  • SG is acceptable option as a primary bariatric
    procedure
  • SG has a risk/benefit profile that lies between
    LAGB and RYGB
  • Long-term weight regain can occur and, in the
    case of SG, this could be managed effectively
    with re-intervention
  • Informed consent for SG used as a primary
    procedure should be consistent with consent
    provided for other bariatric procedures and
    should include the risk of long-term weight gain

9
Criticisms
  • Earlier data suggest SG only half as good as DS
  • Lack of long term data does not justify this
    approach
  • Why base program on operation where we expect
    failure to be 30
  • Poor outcomes have the potential to tarnish image
    of bariatric surgery
  • SG complications though rare can be very
    challenging to manage

10
Expected Excess Weight Loss
Brethauer et al. Surg Obes Relat Dis 2009
11
Bougie
  • The bougie is positioned on the lesser curve
    distal to the point of transection
  • Too large will decrease expected weight loss
  • Too small will increase risk of post-op nausea,
    stenosis and leak
  • Most surgeons use 32-40F (range 30-60F)

12
Michigan Bariatric Surgery Collaborative
  • Comparative effectiveness analysis of the safety
    and effectiveness of SG, RYGB, and LAGB
  • 9,000 patients matched on preoperative risk
    factors and predictors of weight loss outcomes to
    deal with the issue of selection bias
  • Outcomes included complications occurring within
    30 days, weight loss, comorbidity resolution,
    quality of life, and patient satisfaction at 1,
    2, and 3 years follow-up

13
Michigan Bariatric Surgery Collaborative
  • Overall complication rates among patients
    undergoing SG (6.3) were significantly lower
    than for RYGB (10.0, plt0.0001) but higher than
    for LAGB (2.4, plt0.0001)
  • Serious complication rates were similar for SG
    (2.4) and RYGB (2.5, p0.736) but higher than
    for LAGB (1.0, plt0.0001)
  • Excess body weight loss at 1-year was 69 RYGB,
    60 SG, and 34 LAGB
  • SG was similarly closer to RYGB than LAGB with
    regard to resolution of obesity-related
    comorbidities, quality of life, and patient
    satisfaction

14
Co-morbidity Remission and Improvement
Brethauer et al. Surg Obes Relat Dis 2009
15
Long-term follow-up after SG
16
NEJM, Vol 351, No.26, December 23, 2004
17
Weight Change ()
18
Unacceptable Failure Rate
  • What definition of failure?
  • EWL lt 50
  • Persistent co morbidities
  • Lack of lifestyle modification (diet exercise)
  • How does the failure rate compare?
  • SG 25-30
  • RYGB 20
  • LAGB 35-40
  • Causes of failure are multifactorial
  • Addressing anatomical issues without addressing
    lifestyle issues likely result in poor long term
    outcomes

19
Poor Outcomes Tarnish Bariatric Surgery
  • Weight regain though frustrating is accepted
    complication of bariatric procedures
  • Debilitating complications like anemia secondary
    recalcitrant ulcers and internal hernias
    resulting in short gut syndrome can have a
    negative lasting effect
  • Nutritional and Vitamin deficiency requiring
    hospital admission for management also tarnish
    image

20
Managing Leaks is Challenging
  • Early lt 48h
  • repair, drain /- j tube for feeding
  • Late gt 4 days
  • drain j tube for feeding

21
Options if Drainage Persists
  • Refer to center with experience in endoscopic
    stenting, clips, glue
  • If persists, consider RYGB
  • Stoma appliance

22
Nova Scotia SG Program
  • The best option for morbidly obese patients is to
    have access to bariatric surgery program in their
    home province
  • Patients who do not develop healthier lifestyle
    (diet and exercise) will fail any operation over
    the long term
  • Patients undergoing malabsorptive procedures
    should have access to long term follow-up
  • Deaths or significant number of complications
    would could potentially shut down program

23
NS Experience
  • 166 patients
  • 136 female (82)
  • Mean age 44 years (range 16-68, SD 10)
  • Mean pre-operative BMI 49.6 (range 23.9-73.5, SD
    7)
  • Mean operative time 93 min (range 56-232, SD 33)
  • Mean hospital stay 2.6 (2-8, SD 0.8) days
  • Reoperation rate 1.8

24
Complications
Complication Number ()
Staple line leak 1 (0.6)
Bleeding 2 (1.2)
Sleeve stenosis 0
Death 0
Minor 7 (4.2)
Total 10 (6)
25
Postoperative follow-up
Time (months postop) EWL (Range, SD) Number of patients/ Total eligible ()
6 49.3 (18.9-92.4, 13) 99/140 (71)
12 54.24 (0.7-95.9, 19) 59/109 (53)
24 64.4 (38.3-101, 31) 12/44 (27)
26
Summary
  • SG is acceptable option as a primary bariatric
    procedure
  • SG has a risk/benefit profile that lies between
    LAGB and LRYGB
  • Long-term weight regain can occur and, in the
    case of SG, this could be managed effectively
    with re-intervention

27
Thank you
  • James Ellsmere, MD MSc FRCSC
  • James.Ellsmere_at_dal.ca

28
Selection Criteria
Factor Criteria
Weight (adults) BMI gt 40 kg/m2 with no comorbidities BMI gt 35 kg/m2 with obesity-related comorbidity
Weight Loss History Failure of previous nonsurgical attempts at weight reduction, including nonprofessional programs (i.e. Weight Watchers)
Commitment Expectation that patient will adhere to post-op care Follow-up visits with physician's and team members Recommended medical management, including the use of dietary supplements Instructions regarding any recommended procedures or tests
Exclusion Reversible endocrine or other disorders that can cause obesity Current drug or alcohol abuse Uncontrolled, severe psychiatric illness Lack of comprehension of risks, benefits, expected outcomes, alternatives, and lifestyle changes required with bariatric surgery
29
Nova Scotia WLS Program
  • BMI gt 60
  • Challenging to perform high quality sleeve with
    low complication rate
  • Patients counseled and offered medically
    supervised diet/exercise plan
  • Graduate 50 from program with excellent outcomes
  • BMI 35 60
  • Goal 10lb weight loss prior to sleeve

30
Outcomes
Brethauer et al. Surg Obes Relat Dis 2009
31
Access and Port Placement
Karmali et al. Can J Surg 2010
32
Mobilization of the Greater Curvature
33
Distal Transection Point
  • The distal transection point is measured relative
    to the pylorus
  • Too long will decrease expected weight loss
  • Too short may effect gastric emptying
  • Most surgeons start 5 cm (range 1-10 cm) proximal
    to the pylorus

34
Bougie
  • The bougie is positioned on the lesser curve
    distal to the point of transection
  • Too large will decrease expected weight loss
  • Too small will increase risk of post-op nausea,
    stenosis and leak
  • Most surgeons use 32-40F (range 30-60F)

35
Stapling
  • The goal is the creation of a uniform gastric
    tube
  • Requires optimal visualization and lateral
    traction on the stomach
  • Avoid the esophagus - leave 1 cm of fundus as
    precaution

36
Staple Line Reinforcement
  • Staple-line was reinforced by 65.1 of the
    surgeons of these, 50.9 over-sew, 42.1
    buttress, and 7 do both
  • Several series without buttress material with 1
    bleeding rate, 1 leak rate
  • Consider optimal staple height, need for tissue
    compression, clipping bleeders and selectively
    oversewing

Gagner et al. Surg Obes Relat Dis 2009
37
Staple Line Testing
  • Intraoperative leak testing with air
    (gastroscope) and/or methylene blue dye
  • Consider leaving drain

38
Removing Specimen
39
Sleeve Gastrectomy and Hiatal Hernia Repair
  • Small cases series
  • Morbid obesity is risk factor for failed hiatal
    hernia repair
  • If large or symptomatic hernia and BMI gt 35,
    hernia repair sleeve is an option
  • Post op course similar to sleeve alone

40
Band to Sleeve
  • Small case series
  • Risk of complications higher than primary
    operation
  • If treating band complications, consider two
    stage approach
  • Avoid stapling through compromised tissue

41
Low Rate of Complications
  • High leak occurred in 1.5
  • Lower leak in 0.5
  • Hemorrhage in 1.1
  • Splenic injury in 0.1
  • Stenosis in 0.9
  • GERD _at_ 3 mo 6.5 (range 0-83)
  • Mortality was 0.2 /-0.9

Gagner et al. Surg Obes Relat Dis 2009
42
Patient Decision
  • Boils down to tolerance for risk and perceived
    risk reward
  • Bariatric vs non-operative management question is
    clear
  • Whats the best bariatric surgery for the patient
    is difficult to know

43
Perioperative Outcomes of Laparoscopic Sleeve
Gastrectomy, Effectiveness in Short to Medium
Term Weight Loss and Improvement in Diabetes
Mellitus
  • C. Hoogerboord MB ChB, MMed, S. Wiebe MD, D.
    Lawlor NP,
  • R. Stewart BSc, T. Ransom MD, D. Klassen MD,
    J. Ellsmere MD, MSc (jellsmer_at_dal.ca)
  • Department of Surgery, Division of General
    Surgery, Dalhousie University, Halifax NS

44
Introduction
  • Laparoscopic Sleeve Gastrectomy (LSG) is
    increasingly being performed as a stand-alone
    bariatric procedure with short and medium term
    weight loss and improvement in obesity associated
    comorbidities comparable to Laparoscopic
    Roux-en-Y Gastric Bypass, (LRYGBP) the current
    gold standard in bariatric surgery.

45
Discussion
  • LSG is gaining popularity as a final surgical
    treatment for morbid obesity
  • Complications are infrequent but most significant
    for staple line leak (2), bleeding (1.2),
    sleeve stenosis (0.8) and death (0.19)1.

Gagner et al. Surg Obes Relat Dis 2009
46
  • Effectiveness as weight loss procedure confirmed
    by several studies, 12 and 24 month EWL 55.8 and
    52.4 respectively in a systematic review of
    Brethauer et al2. More than weight loss seen
    with LAGB but somewhat less than with LRYGBP3.
  • Concept of metabolic surgery now recognized by
    endocrine specialists. LSG led to 2 year
    remission rate of Type 2 DM of 75 vs 0 with
    optimal medical therapy in patients with BMIgt354.

47
Aim
  • To review our experience with Laparoscopic
    Sleeve Gastrectomy (LSG) in terms of
    perioperative outcomes, effectiveness in inducing
    weight loss and improvement or resolution of
    Diabetes Mellitus (DM) over a two year period

48
Methods
  • A retrospective review of prospectively recorded
    data was performed for all patients who underwent
    LSG from September 01, 2007 to June 30, 2011
  • Patient demographics and perioperative data were
    collected.
  • Postoperative follow-up data was obtained at 6,
    12 and 24 months and included Percentage Excess
    Weight Loss (EWL) for all patients
  • In the subgroup of 85 patients with a
    preoperative diagnosis of DM, additional data
    included HbA1c, AC Glucose and improvement or
    resolution of Diabetes
  • Improvement of DM was defined as a decrease in
    dose or number of anti-diabetic drugs required to
    control serum glucose whereas resolution was
    defined as normalization of AC glucose
    (lt5.6mmol/l) and HbA1c (lt6.5) with
    discontinuation of all anti-diabetic drugs

49
Perioperative Results
  • 166 patients
  • 136 (82) female
  • Mean age 44 (range 16-68, SD 10) years
  • Mean pre-operative BMI 49.6 (range 23.9-73.5, SD
    7)
  • Mean operative time 93 (Range 56-232, SD 33)
    minutes.
  • One (0.6) conversion to laparotomy
  • Mean hospital stay 2.6 (2-8, SD 0.8) days.
  • Reoperation rate 1.8.

50
Complications
Complication Number ()
Staple line leak 1 (0.6)
Bleeding 2 (1.2)
Sleeve stenosis 0
Death 0
Minor 7 (4.2)
Total 10 (6)
51
Postoperative follow-up
Time (months postop) EWL (Range, SD) Number of patients/ Total eligible ()
6 49.3 (18.9-92.4, 13) 99/140 (71)
12 54.24 (0.7-95.9, 19) 59/109 (53)
24 64.4 (38.3-101, 31) 12/44 (27)
52
Time (months postop) HbA1c (Range, SD) Number of patients/Total eligible ()
0 7.6 (4.5-14.0, 1.7)
6 6.3 (4.5-10.4, 1) 50/66 (77)
12 6.5 (4.4-9.5, 1.2) 27/52 (52)
24 6.2 (5.2-6.6, 0.5) 2/19 (11)
53
Time (months postop) AC Glucose (mmol/l) (Range, SD)
0 8.3 (3.3-21.5, 2.9)
6 6.4 (2.2-22.0, 2.2)
12 6.9 (3.7-14.3, 2.3)
24 5.6 (4.2-6.3, 0.7)
54
Diabetic outcomes at 12 months postop
  • Resolution 21/27 (78)
  • Improvement 2/27 (7)

55
Conclusion
  • LSG can be performed safely with acceptable
    complication rates at our institution
  • It is an effective bariatric procedure and can
    play an important role as metabolic therapy for
    DM
  • Longer term studies are needed

56
Healthcare Economics
  • Surgery is one arm of an expensive
    multidisciplinary intervention
  • Reoperative outcomes are not as good as primary
    interventions in part because patient group
    already failed multidisciplinary intervention
  • It may be more cost effective to offer the
    multidisciplinary intervention to a new person on
    the wait list vs revise someone who failed
Write a Comment
User Comments (0)
About PowerShow.com